MicuRx Pharmaceuticals, Inc.
Better Therapy Through Superior Medicines
Zhengyu Yuan, Ph.D. - President and Chief Executive Officer
Dr. Yuan has more than 19 years of experience in drug discovery and development, with a strong emphasis on the efficient
identification of clinical development candidates in several therapeutic fields. He was the founding scientist of
Vicuron Pharmaceuticals Inc. (formerly Versicor), and Senior Vice President of Research, before Vicuron was acquired
by Pfizer at the end of 2005.
In the last three years, he lead the Vicuron Fremont R&D team that identified 7 clinical development candidates.
In addition, the team under his leadership has made major breakthroughs in several other pre-clinical projects.
Dr. Yuan has pioneered the discovery of peptide deformylase (PDF) inhibitors as a new class of antibacterial agents
which entered the human clinical trials. He has a strong record of achievements in the rational drug design,
biochemistry, and pharmacology.
Prior to joining Vicuron, Dr. Yuan has worked at Syntex, Affymax, and GlaxoWellcome. He received his Ph.D.
degree in Biochemistry from Cornell University and B.S. degree in Chemistry from Fudan University. Dr. Yuan has
authored eleven patents and more than 35 peer-reviewed publications.
Mike F. Gordeev, Ph.D. - Chief Scientific Officer
Dr. Gordeev has been one of the scientific founders of Vicuron Pharmaceuticals Inc. (formerly Versicor Inc.).
His industrial and academic career spans over 22 years. In recent years, he has served as Vice President of
Chemistry of Vicuron, where Dr. Gordeev has led several successful drug discovery programs, both internal and
that in collaboration with Novartis and Pfizer (which subsequently acquired Vicuron). This work has resulted in
the identification of several clinical compounds, including the best-in-class lincosamides, oxazolidinones, and
first-in-class PDF inhibitors. As a member of the global Vicuron IND team, Dr. Gordeev also managed pre-clinical
chemistry in support of the corporate development team.
Prior to Vicuron, he has led groups of GlaxoWellcome and Affymax scientists in a pioneering research on the
application of combinatorial chemistry in multiple medicinal chemistry programs.
Prior to his USA biopharma experience, Dr. Gordeev has held a sr. scientist position at the Zelinsky Institute
of Organic Chemistry of the Russian Academy of Sciences (Moscow), and then served as a group leader at
the Prof. Katritzky's Center for Heterocyclic Compounds (Univ. of Florida, Gainesville).
He received his M.S. and Ph.D. degrees in Organic Chemistry from the Moscow State University (Moscow, Russia).
Dr. Gordeev has authored in excess of 100 scientific publications and patents in areas of medicinal,
bioorganic, and synthetic chemistry.
This is the future official site for MicuRx Pharmaceuticals, Inc. UNDER CONSTRUCTION! |
